Rimonabant

Overview

Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.

Indication

For use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m, or patients wih a BMI greater than 27 kg/m with associated risk factors, such as type 2 diabetes or dyslipidaemia.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Effects of CB1 Antagonist/Reverse Agonist Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury	2022/11/21	NCT05622994	Phase 2	Not yet recruiting	Hospital Nacional de Parapléjicos de Toledo
Effects of Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury	2022/06/01	NCT05398913	Phase 1	Completed	Hospital Nacional de Parapléjicos de Toledo
Antagonist-Elicited Cannabis Withdrawal	2009/12/31	NCT01041170	Phase 1	Completed	National Institute on Drug Abuse (NIDA)
Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes	2008/09/18	NCT00754689	Phase 3	Withdrawn	Sanofi
Antagonistic Interaction CB1-paracetamol	2008/09/10	NCT00750347	Phase 1	Completed	University Hospital, Clermont-Ferrand
Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases.	2008/08/14	NCT00734123	Phase 4	UNKNOWN	Hospital Arnau de Vilanova
Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes	2008/06/04	NCT00690456	Phase 3	Terminated	Sanofi
Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients	2008/05/15	NCT00678483	Phase 3	Terminated	Sanofi
Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults	2008/04/11	NCT00656487	Phase 2	Completed	The Scripps Research Institute
Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque	2008/03/14	NCT00636766	Not Applicable	Completed	Aristotle University Of Thessaloniki

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

MIRA Pharmaceuticals Unveils Preclinical Data for SKNY-1, Targeting Obesity and Smoking Cessation Without CNS Side Effects

a month ago

MIRA Pharmaceuticals announced new in vitro preclinical data from Eurofins demonstrating SKNY-1's potential as a first-in-class oral therapy for obesity and nicotine addiction without central nervous system side effects.

Corbus Pharmaceuticals Initiates Phase 1 Trial of Peripherally Restricted CB1 Inverse Agonist for Obesity

4 months ago

Corbus Pharmaceuticals has dosed the first subject in a Phase 1 trial of CRB-913, a second-generation CB1 inverse agonist designed to treat obesity while avoiding neuropsychiatric side effects.

CB1 Inhibitors Resurface as Potential Obesity Treatment with Improved Safety Profiles

10 months ago

• A new generation of CB1 receptor inhibitors is being developed by companies like Novo Nordisk, Corbus Pharmaceuticals, and Skye Bioscience for obesity treatment. • These new therapies aim to avoid the neuropsychiatric side effects seen in previous CB1 inhibitors by targeting peripheral receptors instead of those in the brain. • Early clinical trial results for drugs like nimacimab and monlunabant show promise in weight loss with varying degrees of neuropsychiatric side effects. • Combining CB1 inhibitors with GLP-1 drugs like Wegovy and Zepbound may offer enhanced weight loss and metabolic benefits, according to preclinical and early clinical data.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access